Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.

Explor Target Antitumor Ther · 2024 · PMC11702265 · PMID 39764422

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Preliminary results from the ATLANTIS trial demonstrated that maintenance rucaparib extended median PFS compared to placebo, although this improvement did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.